Ricin, the highly toxic glycoprotein from the castor bean Ricinus communis, has been studied extensively at both cellular and molecular levels. Binding of the B-chain glycoprotein to cell surface receptors results in the internalisation and translocation of toxic A chain to its intracellular site of action. Ricin A-chain enzymically inhibits protein synthesis by inactivation of the 60S ribosomal subunit (Sperti et al., 1973) . This is achieved by cleavage of an adenine base residue from the 28S ribosomal subunit (Endo et al., 1987) .
Ricin has been extensively studied as a potential agent for the treatment of malignancy. When used in laboratory rodents, ricin successfully inhibited growth of Ehrlich ascites tumour cells (Lin et al., 1970; Fodstad et al., 1977) . Adjuvant therapy with adriamycin significantly enhanced the lifespan of animals inoculated with leukaemic cells (Fodstad & Pihl, 1980a) . Ricin treatment suppressed the growth of human tumour cell lines growing as xenografts in athymic mice (Fodstad et al., 1980b,c (Fodstad et al., 1984) .
In an attempt to improve the efficacy of ricin therapy, various methods have been employed to target ricin to specific sites of action. Immunotoxins have been prepared linking ricin, either as holotoxin or A-chain, to monoclonal antibodies against cell surface antigens. This approach has been utilised in vitro to kill contaminating leukaemic cells (Kronke et al., 1985; Press et al., 1986; Katz et al., 1987) from human bone marrow. Ex vivo treatment of bone marrow with immunotoxin directed against immunocompetent T lymphocytes has successfully prevented graft-versus-host disease in allogeneic recipients (Vallera et al., 1981; Fillipovich et al., 1984) .
Another method of targeting is to utilise a migrating population of cells as vehicles to carry material to a particular site in the body. Lymphocytes can be used to carry toxins or radioisotopes to lymphoid tissue (Ford, 1985) . Radiolabelled lymphocytes migrate normally for a variable period during which time 80%-90% gain access to lymphoid tissue (Rannie & Donald, 1977; Birch et al., 1986) . This method has been successfully employed to deposit radioactive isotopes in spleen and lymph nodes (LN) of normal subjects and patients with lymphoma and leukaemia for diagnostic purposes (Lavender et al., 1977; Wagstaff et al., 1981a,b) . This is currently being developed at the Christie Hospital, Manchester, for therapeutic purposes (Hamilton et al., 1988). Mammalian cells internalise ricin which is later liberated in a form that is toxic to a second cell population (McIntosh et al., 1984) . Sparshott et al. (1985) demonstrated that lymphocytes loaded with ricin and trace-labelled with 51Cr retained their normal migratory characteristics in vivo at early time intervals following injection. These results based on 5'Cr localisation, suggested that ricin was delivered in high concentrations to lymphoid tissues. The resulting histological changes of lymphoid destruction observed in spleen and LN supported this view. Adoptive transfer of lymphocytes bearing ricin successfully inhibited Moloney-murine sarcoma virus induced tumours in vivo (Cerundolo et al., 1987) .
In order to assess the efficiency of ricin targeting by lymphocytes the distribution of '25I-ricin on cells was compared with the distribution of free radioiodinated ricin in vivo. The aim of the investigation was to develop means of increasing the ricin concentration in spleen and LN while minimising localisation to the liver and bone marrow.
Materials and methods

Ricin
The toxin Ricinus communis was prepared from the defatted castor bean cake according to the procedures described in detail by Cumber et al. (1985) . Ricin was kindly supplied by Dr A. Forrester and Professor A.J.S. Davies from the Chester Beatty Cancer Research Laboratory, and at a later stage by Dr P. Thorpe from the Imperial Cancer Research Foundation, London.
Radiolabelling ricin holotoxin Ricin was radioiodinated by a protocol based on the iodogen method (Johnstone & Thorpe, 1982) . Ricin (1.5mgml1' in PBS) was added to an iodogen tube containing sufficient powdered lactose, to give a final concentration of 100 mmol. 1 mCi 125I (Amersham, Code NoIMS30, specific activity approx 16 mCi pg-of iodine) was added and incubated on ice for 1 h. Free 1251 and lactose were separated from '25I-ricin conjugate on a P6 acrylic column equilibrated with 0.6 M sodium acetate buffer. Protein concentration was estimated by spectrometry (LKB Ultrospec 4050) and the specific radioactivity determined. Animals Rats of the highly inbred AO or PVG strains (RT1U and RT1C respectively) were bred and maintained in the University of Manchester Animal Unit.
Thoracic duct cannulation This was performed by Gowan's method (Ford, 1978) . Thor Cell labelling with radioiodinated ricin enabled quantitation of ricin uptake. The rate of ricin uptake was determined by the regular removal of samples during a 4 h incubation period. An incubation ricin concentration of 25 Itg 10-8 cells was found to be optimal since higher concentrations were known to impair lymphocyte migration to LN, whilst lower concentrations would have necessitated impractically large numbers of TDL to provide a therapeutic dose (Sparshott et al., 1985) . Previous studies demonstrated that 1251-labelled ricin was equal in toxicity to native ricin (Ramsden et al., 1989 .
Release of ricin and chromium-SI from lymphocytes '25I-Ricin-loaded TDL were held in vitro at 37°C and ricin release determined. Radioactivity detected in the supernatant was expressed as a percentage of the total radioactivity per sample. In the same way, an estimation of 5'Cr label released from passaged TDL was made. The release of chromium is indicative of cell death and is similar to that of a cytotoxic release assay both in vitro and in vivo (Rolstad, 1985) .
Tissue distribution of radioactivity Rats injected i.v. with free or cell associated '25I-ricin were anaesthetised, a blood sample obtained by aortic puncture and killed by aortic transection. Individual organs were separated cleanly from adjacent structures, removed, weighed and the amount of radioactivity determined by gamma counting (LKB Ultragamma 1250 dual channel gamma spectrometer). Pulse height analyser facilities for each channel, and automatic comparison for each channel with reference samples allowed discrimination between isotopes (5"Cr and 251) when necessary. Results were expressed as a percentage of the injected dose per gram to reflect the relative concentration in different tissues.
In vitro studies: inhibition ofprotein metabolism by ricin Incorporation of 3H Leucine (Leu) 100 fL aliquots of leucine-free culture medium with or without ricin (37.5 jig ml-') were distributed in a 96 well microtitre plate and incubated at 37°C in the presence of 5% CO2. TDL (50 Ll of 5 x 106 ml-' in leucine-free medium) were added to each well. Wells were pulsed with 3H Leu (10 iCiml1', Amersham, Code No TRK 170, Specific activity 70 Ci mmol-' leucine). Cell cultures were harvested at 10min intervals in the first hour and at 1, 2, 3, and 5 h thereafter. 3H Leu incorporation was measured by scintillation counting a Beckman counter (LS 1801).
Results
In vitro uptake of ricin by TDL The uptake of ricin by cells was studied by incubating TDL in RPMI + 10% FCS containing '251-ricin (25 yg 10-8 cells) for varying periods. Less than 1% of the ricin was internalised (142 ng to 185 ng 10-8 cells) by 15 min (Figure 1 ). Ricin incorporation followed an exponential curve, linear in the first 15 min but levelling off at 30 min; increasing amounts were internalised as late as 4 h.
Since galactose side chains present on serum proteins might compete with cells for ricin binding, TDL were incubated with '25I-ricin in a medium containing no FCS. Ricin uptake was increased 4-5 fold (800 ng 10-8 cells, or 3.2% of total). However as indicated later, the absence of protein in the medium had a deleterious effect on lymphocyte migration in vivo.
The distribution of ricin following i.v. injection of ricin-loaded TDL The systemic distribution and kinetics of free '251I-ricin in rats was reported previously (Ramsden et al., 1989) . We compared this distribution with that of 251I-ricin transported in vivo by syngeneic TDL. In a number of tissues, notably blood (both cell associated and plasma), heart, muscle and bone marrow, the localisation of ricin, targeted by cells (Table I) or injected free (Ramsden et al., 1989) was similar. Tissues where significant differences in ricin distribution resulted from the transport of ricin on cells are illustrated in Figure 2 . At 1 h the localisation of ricin carried to the liver a 10- 1985) . In these earlier experiments unlabelled ricin was loaded into 5'Cr-labelled TDL and the ultimate distribution of ricin was inferred from the distribution of 51Cr. In order to clarify the discrepancy a double-labelled experiment was designed to allow for a direct comparison. I251-ricin was loaded into passaged 51Cr-labelled TDL. These double-labelled cells were injected into four groups of five animals each; groups were killed at 4, 2, 12 and 24 h (Figure 3) . 5'Cr tissue concentrations were used as an indicator of localisation of the TDL. In comparison with published migration kinetics using 5"Cr TDL (Smith & Ford, 1983) , the ricin-loaded TDL localised in spleen and LN almost normally during the first 2 h after injection (Figure 3) . The migration pattern differed at subsequent periods in that ricinloaded TDL failed to be redistributed from spleen to LN, reflecting the toxic effects of ricin on lymphocyte mobility. Figure 3 shows an enormous discrepancy between 5"Cr and '25I-ricin distribution. At I h spleen and lymph nodes contained high 5"Cr levels, whereas "'I-ricin levels were only 50% and 30% of 51Cr values, respectively. The level of localisation of 51Cr and 1251 was reversed in the liver (0.9% 5"Cr; 3.7% ricin), bone marrow (4.2% 5'Cr; 8% ricin), blood (0.6% 5'Cr; 1.1% ricin) and kidney (0.3% 51Cr; 0.7% ricin).
Furthermore, while 51Cr tended to be retained in lymphoid organs and the liver, '25I-ricin was rapidly eliminated after 2 h. These results indicate that ricin rapidly dissociated from the lymphocytes after injection, even before they entered lymphoid tissue. Ricin that was transported to lymphoid (Ramsden et al., 1989) . Each point represents the mean ± s.e. of five samples.
by TDL was 30% less than that resulting from i.v.-injection of free ricin. This difference persisted over the next 12 h. There was a doubling of the activity found in the lung at all time intervals, reflecting lymphocyte entrapment within the pulmonary vasculature. Renal localisation following injection of ricin loaded lymphocytes was persistently half that resulting from use of free ricin. In lymphoid tissue we observed a considerable concentration of ricin by targeting with TDL. There was a doubling in the spleen, a 4-fold increase in the cervical LN and 10-fold increase in Peyer's patches.
Simultaneous localisation of '251-ricin and "Cr by lymphocytes
In the above experiments the increase in lymphoid localisation of ricin, achieved by lymphocyte targeting, was considerably less than that suggested previously (Sparshott et al., tissues was retained for up to 2 h but then rapidly released.
In contrast 5"Cr was present for longer periods and released at the time of cell death. It was estimated that about 70% of transported ricin had dissociated from the cells within 0.5 h of injection.
This early release of ricin seriously reduces the efficiency of concentrating ricin in lymphoid tissue. Therefore, we have investigated the early release of ricin and the effect of ricin on TDL in vitro.
In vitro release of 5'Cr and '25I-ricin Passaged 5"Cr-labelled TDL, were loaded with 251I-ricin, washed and incubated in suspension at 37°C. Samples were removed at regular time intervals, centrifuged and both supernatant and cell pellet counted. Release of ricin from TDL in the first 20 min was rapid (Figure 4) and continued but at a slower rate, so that by 120 min 60% had dissociated. The loss of 51Cr during this period was minimal; 4% release by 2 h. The in vivo release of ricin from TDL by half an hour was 70%, although only 35% release was noted in vitro.
Effect of ricin on 51Cr TDL The effect of ricin on 51Cr-TDL was studied by observing the release of 51Cr in vitro during 24 h of culture. 51Cr-labelled than 5% of 5"Cr was released from ricin-loaded TDL, but with time the loss of 5"Cr from these cells increased faster than the release from control cells. By 24 h 85% of 5"Cr had been released as a result of ricin loading compared with 45-50% from control cells. Maximum 51Cr release in vitro occurred by 12-24 h correlating closely with the timing of 5'Cr loss from lymphoid tissues and its appearance in kidney in the in vivo situation.
Rapid release of ricin from TDL The in vitro incubation of TDL loaded with ricin showed two phases of release, an early exponential phase (first 40 min) followed by a slow release phase (Figure 4) . We asked whether, by allowing the rapid phase to occur in vitro for 40 min before transfer, the selective localisation of ricin to lymphoid tissues by TDL could be improved. Initially we showed that in vitro incubated ricin TDL, when washed and incubated in vitro for a further 40 min, continued to release ricin at a slow steady rate and did not revert to the rapid release phase. Therefore, '25I-ricin-loaded TDL were tested in vivo after receiving a 40 min incubation step. The 125_I localisation from standard 1251-ricin TDL and the 40 min incubated 125I-ricin TDL was no different (Table II) . Allowing an early in vitro elution of ricin did not prevent a further elution of ricin in vivo, nor improve the targeting of ricin to lymphoid tissue.
Effect of ricin on the kinetics ofprotein synthesis In the following experiments the effect of ricin on protein metabolism was examined in an attempt to determine whether there was a correlation with loss of migratory ability, release of ricin, or death of the cell. Protein synthesis was assessed by 3H-leucine (3H-Leu) incorporation. 3H-Leu was added to cultures of TDL, with or without added ricin (25 gml-').
Ricin free cultures incorporated 3H-Leu linearly from 5 min to 5 h. The addition of ricin did not affect 3H-Leu incorporation during the first 40min, but by 60min, 3H-Leu incorporation had peaked at 70% of the ricin free culture. No further incorporation was detected in the presence of ricin during the subsequent 4 h (Figure 6 ). In view of the early inhibition of protein synthesis by ricin, the handling time required to load ricin could be critical to the success of ricin targeting in vivo. Using a revised protocol in which the handling time was shortened from 60 min to 21 min, we were unable to increase the proportion of 1251_ ricin delivered to LN or spleen in the I h period after injection (data not shown).
Discussion
Lymphocytes provide a powerful tool for targeting materials to lymphoid tissue since, following injection into the bloodstream, they localise in spleen and lymph nodes at a concentration approximately 500 times greater than that averaged over the whole body (Ford, 1985) . Ninety percent of this targeting is achieved within 1 h of injection, generating lymphoid concentrations 25,000 times that of non-lymphoid tissues such as a muscle. We have clearly failed to achieve this efficiency with ricin targeting by lymphocytes, but have observed some success and identified the problem areas. The first requisite of lymphocyte targeting is that the cells should be able to take up the material concerned. In vitro incubation with ricin results in lymphocyte-uptake of less than 1% of the total ricin. This is not in itself a problem but necessitates that, for clinical use, the ricin be trace-radiolabelled in order to know precisely the dose which will be administered to the recipient.
The second requisite is that ricin should not unduely affect the migration properties of lymphocytes in the first hour or so after injection. The quality of the lymphocytes is important to this area since in vitro handling in itself reduces the migratory potential of lymphocytes. Ford, 1983) . In clinical studies it is fortunate that lymphocytes freshlyisolated from peripheral blood are equally endowed with good migratory properties (Wagstaff et al., 1981a,b) . It is also clear from the present results, especially Table III , that neither the in vitro handling involved in loading lymphocytes with ricin nor the toxicity of ricin itself significantly affect early migration. This is perhaps surprising in the light of the severe and early effects of ricin on protein synthesis by lymphocytes and other cells (Olsnes et al., 1976) , but nevertheless indicates that the observed shortfall in targeting efficiency for ricin cannot be accounted for by failure of the lymphocytes themselves to reach lymphoid tissues.
It is the dual labelling experiment with 251I-ricin 51Cr-labelled passaged lymphocytes which has elucidated the major problem of early in vivo release of ricin from their lymphocytic vehicles before those lymphocytes reach lymphoid tissues (Figure 3) results that ricin is released from ricin loaded lymphocytes albeit mostly at an early stage and systemically and not in lymphoid tissue. The timing of that release is not particularly related to the cessation of protein synthesis or to the final death of the cells which, by 5'Cr studies both in vitro and in vivo, probably occurs around 12 h after ricin loading. Ricin which is carried into lymphoid tissues on carrier lymphocytes reaches there within an hour of injection. Subsequent loss of that ricin from lymphoid tissues occurs with identical kinetics to those for free ricin (Figure 2 ). Whether this represents direct loss from carrier lymphocytes into the blood stream or includes an intermediate passage through surrounding cells is uncertain but the similarity of the kinetics suggests the former alternative to be quantitatively more important. This work illustrates many of the potential pitfalls in using lymphocytes to target materials in general and ricin in particular. We have identified the main reasons for the shortfall in potential efficiency of lymphocyte targeted ricin, though unfortunately have not been able to overcome the problems involved. Despite these limitations, distribution studies demonstrated successful ricin targeting to lymphoid tissue, with a 4-fold increase in ricin delivered to LN, a 10-fold increase in the Peyers patches, a doubling in the spleen and a 35% reduction of ricin in the liver as compared to free ricin. Ricin is an effective anti-tumour agent in both animal and human tumours and lymphocyte targeting potentially provides a method of treating lymphoid malignancies or micrometastatic lymph node spread from solid tumours.
